U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795412) titled 'Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors' on Jan. 22.
Brief Summary: The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Study Start Date: Feb. 15
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumours
Intervention:
DRUG: PYX-201
Intravenous (IV) infusion.
DRUG: pembrolizumab
IV infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Pyxis Oncology, Inc
Published by HT Digital Content Services with permission from Heal...